Drug intelligence / Profile preview

6-C-(E-phenylethenyl)naringenin

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

6-C-(E-phenylethenyl)naringenin (6-CEPN) is a **styryl flavonoid** compound that represents a hybrid molecule combining stilbene with a flavonoid structure. It is a semi-natural derivative of naringenin that can be found in naringenin-fortified fried beef formed during thermal processing. The compound was identified through computational ligand docking as a **selective cyclooxygenase-1 (COX-1) inhibitor**. 6-CEPN demonstrates multiple mechanisms of action including selective COX-1 inhibition, inhibition of isoprenylcysteine carboxyl methyltransferase (Icmt) leading to RAS pathway suppression, and modulation of Wnt/β-catenin signaling through GSK3β upregulation. The compound has shown anticancer properties in preclinical studies, particularly against colorectal cancer and hepatocellular carcinoma, by inducing cell cycle arrest, autophagy, and inhibiting cancer cell stemness. It also exhibits anti-inflammatory effects through upregulation of the Nrf2 signaling pathway and inhibition of advanced glycation end product (AGE)-induced inflammation. Notably, 6-CEPN possesses higher bioavailability than its parent compound naringenin and has been well-tolerated in animal studies without significant gastrointestinal or systemic toxicity.

Other names
6-C-(E-phenylethenyl)-naringenin
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ICMT (Isoprenylcysteine carboxyl methyltransferase)AGER (RAGE)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)PGHS-1 (Prostaglandin G/H Synthase 1)MAPK3 (Mitogen-activated protein kinase 1)

Beyond the preview

Go deeper on 6-C-(E-phenylethenyl)naringenin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 6-C-(E-phenylethenyl)naringenin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call